Chris Schott
Stock Analyst at JP Morgan
(4.10)
# 494
Out of 5,120 analysts
152
Total ratings
65.38%
Success rate
8.47%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $850 → $950 | $753.65 | +26.05% | 9 | Feb 2, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $28 → $35 | $35.27 | -0.77% | 20 | Dec 16, 2025 | |
| PRGO Perrigo Company | Maintains: Neutral | $20 → $18 | $14.17 | +27.03% | 14 | Dec 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,050 → $1,150 | $1,054.06 | +9.10% | 23 | Nov 18, 2025 | |
| OGN Organon & Co. | Maintains: Underweight | $14 → $12 | $8.16 | +47.06% | 3 | Nov 11, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $230 → $200 | $124.29 | +60.91% | 3 | Nov 5, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $675 → $775 | $622.37 | +24.52% | 9 | Nov 4, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $260 | $225.04 | +15.54% | 4 | Nov 3, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $145 → $150 | $142.08 | +5.57% | 8 | Oct 31, 2025 | |
| ELAN Elanco Animal Health | Upgrades: Overweight | $18 → $24 | $24.58 | -2.34% | 4 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $14.16 | -1.13% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $185 → $175 | $179.21 | -2.35% | 4 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $41.91 | +0.21% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $344.99 | -21.74% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $26.45 | +28.57% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $112.50 | +11.11% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $13.54 | +3.40% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $2.28 | +382.46% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.81 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $55.61 | +40.26% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $0.54 | +176,529.17% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.26 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $21.17 | +136.24% | 3 | Nov 2, 2018 |
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Overweight
Price Target: $850 → $950
Current: $753.65
Upside: +26.05%
Teva Pharmaceutical Industries
Dec 16, 2025
Maintains: Overweight
Price Target: $28 → $35
Current: $35.27
Upside: -0.77%
Perrigo Company
Dec 15, 2025
Maintains: Neutral
Price Target: $20 → $18
Current: $14.17
Upside: +27.03%
Eli Lilly and Company
Nov 18, 2025
Maintains: Overweight
Price Target: $1,050 → $1,150
Current: $1,054.06
Upside: +9.10%
Organon & Co.
Nov 11, 2025
Maintains: Underweight
Price Target: $14 → $12
Current: $8.16
Upside: +47.06%
Zoetis
Nov 5, 2025
Maintains: Overweight
Price Target: $230 → $200
Current: $124.29
Upside: +60.91%
IDEXX Laboratories
Nov 4, 2025
Maintains: Overweight
Price Target: $675 → $775
Current: $622.37
Upside: +24.52%
AbbVie
Nov 3, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $225.04
Upside: +15.54%
Gilead Sciences
Oct 31, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $142.08
Upside: +5.57%
Elanco Animal Health
Oct 7, 2025
Upgrades: Overweight
Price Target: $18 → $24
Current: $24.58
Upside: -2.34%
Sep 16, 2025
Maintains: Overweight
Price Target: $12 → $14
Current: $14.16
Upside: -1.13%
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $179.21
Upside: -2.35%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $41.91
Upside: +0.21%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $344.99
Upside: -21.74%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $26.45
Upside: +28.57%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $112.50
Upside: +11.11%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $13.54
Upside: +3.40%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $2.28
Upside: +382.46%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.81
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $55.61
Upside: +40.26%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $0.54
Upside: +176,529.17%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.26
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $21.17
Upside: +136.24%